Big Call Screening: Merck & Co., McDonald’s, ASML, Deutsche Börse
Reading Time: 2 minutes
Merck & Co (MRK) is currently one of the most exciting turnaround stories among the pharma big caps. After the pharmaceutical giant faced significant pressure due to the patent expiration for the oncology blockbuster Keytruda in 2028 and the announced drug price cuts by the U.S. administration, the negative news is likely already priced in. With a strong pipeline and recent acquisitions, the stock presents an interesting opportunity for a contrarian long entry with a leveraged derivative, especially as Merck & Co is currently very attractively...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
